

Prostate Cancer Specialist Publishes New Article 'PSAs and Prostate Cancer: Mayhem and Gore'

/EINPresswire.com/ Dr. Bert Vorstman details steps to consider when patients seek [prostate cancer treatment](#).

A prominent Florida prostate cancer specialist, Bert Vorstman MD, MS, FAAP, FRACS, FACS, has detailed a number of important DECISION MAKING STEPS men should consider about any PSA, prostate cancer evaluation or any prostate cancer treatment. His latest article is a must read and reality check entitled, "PSAs and Prostate Cancer: Mayhem and Gore" how to beat the "healthcare" system and save money.

Dr Vorstman cautions men about the many pitfalls in [PSA evaluation](#) as well as the many risks with undergoing evaluation for prostate cancer and treatment, especially for men with the favorable-risk Gleason 3+3 prostate cancers. "It is very important for men and their partners to consider long and hard as to whether they even wish to have their PSA estimated as some 75% of prostate cancers detected are classed as favorable-risk and are unlikely to need treatment ever," said Dr. Bert Vorstman, a Coral Springs based urological surgeon with some 30 years of experience. "Patients need to be aware of the many negative downstream effects possible from having a PSA blood test taken as well as the unlikelihood of treatment benefit. Men need to be very careful they do not become a victim of unnecessary treatment (over treatment) for their low or favorable-risk Gleason 3+3 prostate cancer."



Dr Vorstman is a dedicated patient advocate and a vocal critic of wholesale PSA testing as well as over treatment of favorable-risk Gleason 3+3 prostate cancers, especially with the scientifically unproven, high-risk, irreversible robotic prostatectomy. A surgical treatment that has marginal, if any benefit and associated commonly with urinary leakage, shortened penis, loss of erections, loss of manhood and negative quality of life issues. Much of this prostate cancer information can be accessed from his premier urology website, www.urologyweb.com/

Dr Vorstman's views are underscored by the recent USPSTF review, explaining the absence of

merits to wholesale PSA screening and for the radical surgical treatment of screen detected prostate cancer in that no significant numbers of lives are saved and only great harm ensues. Furthermore, the great harm and minimal benefit achieved by the robotic prostatectomy for prostate cancer has also been recognized by the legal fraternity resulting in a class action lawsuit against the makers of the robotic equipment.

However, Dr Vorstman feels that this legal action may be somewhat misguided as the great harm associated with [prostate cancer surgery](#) is not so much from the technology used but from the ill conceived radical surgical excision of the prostate itself. "The fact that the significant harm and overall lack of benefits caused by this surgery are not recognized by most urologists in post treatment accountability reviews, is very worrisome indeed." Said Dr Vorstman, "For most men, the risk of lifelong treatment harm from surgery is much greater than the risk of having the common favorable-risk Gleason 3+3 prostate cancer. Most men will outlive their favorable-risk prostate cancer as it has a very long natural history. Except for those men with high-risk cancer who require treatment, the majority of men diagnosed with prostate cancer should undergo periodic monitoring through active surveillance only."

About Dr. Bert Vorstman, MD, MS, FAAP, FRACS, FACS

Dr. Bert Vorstman has a passion to help men and their spouses fully understand the treatment available to them for prostate cancer, as well as the possible complications they face when seeking treatment. To review his complete works on localized prostate cancer go to <http://www.urologyweb.com/exclusive-medical-reports/> or, contact Dr Bert Vorstman at 877-783-4438 or, email him at bvorstmanmd@gmail.com

Media Contact:

Dr. Bert Vorstman

UrologyWeb

877-783-4438

<http://www.urologyweb.com>

Press Release courtesy of Online PR Media: <http://bit.ly/YWvsMp>

This press release can be viewed online at: <https://www.einpresswire.com/article/144169828>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.